Myopia Market

Global Myopia Market Size

The global myopia market size was calculated to be USD 18.97 billion in 2024 and is anticipated to be worth USD 38.71 billion by 2033 from USD 20.53 billion In 2025, growing at a CAGR of 8.25% during the forecast period.

The myopia market exhibits a pronounced presence in Asia-Pacific, North America, and Europe, with Asia-Pacific leading the charge. According to the World Health Organization (WHO), over 90% of teenagers and young adults in East Asia suffer from myopia, making it a public health priority in countries like China, Japan, and South Korea. This prevalence is largely attributed to lifestyle factors, including prolonged near-work activities and limited outdoor exposure. In North America, the American Optometric Association states that approximately 42% of the population is affected by myopia, with urban areas showing higher incidence rates due to increased screen time among children and adolescents. Meanwhile, Europe reflects a moderate but growing trend, with studies published in the British Journal of Ophthalmology indicating a 30-40% prevalence rate across Western European nations. Emerging economies in Latin America and Africa are witnessing rising cases as urbanization accelerates. For instance, a 2021 study in Ophthalmology projected a 50% increase in myopia cases in sub-Saharan Africa by 2030, driven by shifts toward sedentary lifestyles and digital dependency.

MARKET DRIVERS

Rising Prevalence Among Children and Adolescents

The alarming rise in myopia cases among children and adolescents globally is primarily driving the growth of the global myopia market. According to a report by the Brien Holden Vision Institute, nearly 5 billion people worldwide will be myopic by 2050, with half of them progressing to high myopia if current trends persist. A significant contributor to this surge is increased screen time; Common Sense Media estimates that children aged 8-12 spend an average of 5 hours daily on screens, exacerbating eye strain and nearsightedness. Educational pressures in regions like Asia further compound the issue. In China, for example, students often engage in intensive study routines, spending up to 14 hours per day on near-work tasks, as reported by The Lancet. Governments and healthcare providers are responding by investing in preventive measures, such as specialized eyewear and vision therapy programs. These interventions not only cater to immediate needs but also fuel demand for diagnostic tools and corrective devices, propelling growth in the myopia market.

Technological Advancements in Diagnosis and Treatment

Technological advancements are further fueling the expansion of the global myopia market. Innovations in diagnostic equipment, such as optical coherence tomography (OCT) and wavefront aberrometry, enable early detection of refractive errors with remarkable precision. Treatment options have also expanded significantly. Orthokeratology lenses, designed to reshape the cornea overnight, have gained popularity, particularly in pediatric care. As per Clinical Ophthalmology, ortho-k lenses reduce axial elongation—a key factor in myopia progression—by up to 50% in children. Additionally, pharmaceutical interventions like low-dose atropine drops show promise, with studies indicating a 60% reduction in myopia progression rates when administered consistently. These breakthroughs attract significant investment from both private and public sectors, fostering innovation and broadening access to cutting-edge solutions.

MARKET RESTRAINTS

High Costs of Advanced Treatments

A significant restraint hindering the myopia market is the prohibitive cost associated with advanced treatments and diagnostic tools. Procedures like orthokeratology and laser-assisted surgeries often exceed $2,000 per patient, making them inaccessible for many families, especially in low-income regions. According to a study published in JAMA Ophthalmology, nearly 40% of households delay or forego treatment due to financial constraints, despite the availability of effective solutions. Moreover, sophisticated diagnostic equipment requires substantial upfront investment, posing challenges for smaller clinics and rural healthcare facilities. For instance, OCT machines can cost upwards of $50,000, limiting their adoption outside major metropolitan areas. This economic barrier restricts market penetration, particularly in developing nations where myopia prevalence is escalating rapidly. Addressing affordability issues could unlock broader accessibility and drive sustainable growth in the industry.

Lack of Awareness About Preventive Measures

The lack of awareness regarding preventive measures and early intervention strategies for myopia is further hampering the growth of the global myopia market. Many parents remain uninformed about the importance of outdoor activities and reduced screen time in mitigating myopia risk. According to a survey conducted by Prevent Blindness, over 60% of parents in the United States were unaware that spending at least two hours outdoors daily could lower the likelihood of myopia development in children. This knowledge gap extends to underserved communities in Asia and Africa, where educational outreach programs are scarce. For example, a report by the International Agency for the Prevention of Blindness revealed that less than 20% of schools in sub-Saharan Africa incorporate vision health education into their curricula. Without proactive efforts to disseminate information, preventable cases of myopia continue to rise, stifling demand for preventive products and services. Bridging this awareness deficit is essential for unlocking the full potential of the myopia market.

MARKET OPPORTUNITIES

Expansion of Telemedicine Services

Leveraging telemedicine to expand access to myopia management services, particularly in remote and underserved areas is one of the major opportunities in the global myopia market. The global telehealth market was valued at $87.7 billion in 2022, offers a robust platform for virtual consultations and remote monitoring of eye conditions, as stated by Fortune Business Insights. For instance, mobile apps equipped with AI-powered vision screening tools can detect early signs of myopia, enabling timely intervention. Telemedicine also addresses workforce shortages in ophthalmology. According to the WHO, there is only 1 ophthalmologist per million people in some African countries, creating a dire need for scalable solutions. By integrating telemedicine with portable diagnostic devices, healthcare providers can offer affordable and accessible care to millions. This approach not only enhances patient outcomes but also drives revenue growth for companies specializing in digital health technologies tailored for eye care.

Growth of Personalized Eyewear Solutions

The development of personalized eyewear solutions, including custom-designed lenses and frames for myopic individuals is another promising opportunity in the global myopia market. The demand for eyewear is rapidly increasing globally, which benefits from increasing consumer demand for stylish yet functional products. Advances in 3D printing and lens customization allow manufacturers to create bespoke eyewear that caters to individual preferences while correcting refractive errors. For example, companies like Warby Parker and Zenni Optical are pioneering online platforms where customers can design their own glasses, incorporating features like blue-light filtering and progressive lenses. A survey by Vision Council found that 70% of millennials prioritize personalized options when purchasing eyewear, highlighting the untapped potential of this niche. By aligning product offerings with evolving consumer expectations, stakeholders can capitalize on this trend and strengthen their position in the competitive myopia market.

MARKET CHALLENGES

Regulatory Hurdles in Product Approvals

Regulatory hurdles are one of the significant challenges to the myopia market, particularly in gaining approvals for new treatments and devices. The stringent evaluation process mandated by agencies like the U.S. Food and Drug Administration (FDA) often delays the launch of innovative products. For instance, clinical trials for low-dose atropine eye drops required over five years of testing before receiving approval, as documented in the journal Ophthalmology. Such delays hinder market entry and increase development costs. Additionally, varying regulatory standards across regions complicate global expansion efforts. Companies must navigate complex frameworks in Europe, Asia, and other markets, each with unique requirements for safety and efficacy. According to Deloitte, compliance-related expenses account for approximately 20% of total R&D budgets for medical device manufacturers. Streamlining these processes could accelerate innovation and ensure wider access to transformative myopia solutions.

Limited Accessibility in Rural Areas

Limited accessibility to myopia care in rural areas presents another pressing challenge, particularly in developing nations. Geographic barriers, coupled with a shortage of trained ophthalmologists, leave millions without adequate eye care services. According to the International Council of Ophthalmology, over 1 billion people worldwide lack access to basic eye exams, disproportionately affecting rural populations. In India, for example, a study published in the Indian Journal of Ophthalmology revealed that rural districts have only one eye care facility per 500,000 residents, compared to urban centers where the ratio is significantly better. This disparity exacerbates untreated myopia cases, leading to avoidable vision impairment. Mobile clinics and community-based initiatives have emerged as partial solutions, but scalability remains an issue due to funding limitations. Bridging this accessibility gap is crucial for addressing the global myopia burden and fostering equitable healthcare delivery.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Type Insights

The simple or developmental myopia segment occupied 64.7% of the global market share in 2024. The domination of the simple or developmental myopia segment in the global market is attributed to its widespread prevalence among school-aged children and young adults, particularly in urban areas. According to a study published in Ophthalmology, nearly 80% of teenagers in East Asia are affected by simple myopia due to prolonged near-work activities like reading and screen time. The primary factor fueling this dominance is the increasing adoption of preventive measures, such as regular eye exams and corrective lenses, which are more accessible for mild to moderate cases of myopia. Additionally, governments and educational institutions are implementing awareness campaigns. For instance, China’s Ministry of Education launched an initiative in 2021 encouraging schools to incorporate outdoor breaks, aiming to reduce myopia rates by 5% annually. These efforts not only address immediate needs but also drive demand for affordable and scalable solutions tailored to developmental myopia.

The pathological or degenerative myopia segment is predicted to register the fastest CAGR of 8.14% over the forecast period owing to the rising awareness about its severe complications, including retinal detachment and macular degeneration. A report by the National Eye Institute highlights that pathological myopia affects 2-3% of the global population, but its impact on vision loss is disproportionately high. Key drivers include advancements in diagnostic tools, such as optical coherence tomography (OCT), enabling early detection of structural changes in the retina. Moreover, innovative treatments like vitreoretinal surgery and gene therapies are gaining traction, addressing previously untreatable conditions. For example, Novartis’ ongoing clinical trials for gene-based interventions target degenerative myopia, attracting significant investment.

By Treatment Insights

The corrective lenses segment was the largest segment and accounted for 70.7% of the global market share in 2024. The dominating position of corrective lenses segment in the global market is attributed to their affordability, accessibility, and ease of use compared to surgical or pharmacological alternatives. The demand for eyewear products is on the rise, with corrective lenses forming the bulk of sales, especially in regions like Asia-Pacific where myopia prevalence is highest. Technological advancements in lens design, such as progressive lenses and blue-light filtering coatings is boosting the expansion of the corrective lenses segment in the global market. Companies like EssilorLuxottica have introduced smart lenses that adapt to varying light conditions, appealing to tech-savvy consumers. Furthermore, government initiatives promoting affordable eyewear contribute significantly; India’s “Vision 2025” program subsidizes corrective lenses for rural populations, reaching over 50 million beneficiaries annually. These trends ensure sustained demand for corrective lenses, solidifying their leadership in the market.

The therapeutics segment is projected to witness a CAGR of 10.8% over the forecast period owing to the innovations in pharmaceutical interventions, particularly low-dose atropine eye drops. Clinical studies published in JAMA Ophthalmology demonstrate that these drops reduce myopia progression by up to 60% in children, making them highly sought after. The development of novel drug delivery systems, such as injectables and sustained-release formulations is also promoting the expansion of therapeutics segment in the global market. For instance, Santen Pharmaceuticals recently launched a long-acting implant for myopia management, targeting compliance issues associated with daily medications. Additionally, regulatory approvals for new therapeutics, coupled with rising healthcare expenditure, create fertile ground for expansion. As awareness grows, therapeutics are set to revolutionize myopia management, outpacing traditional methods.

By Product Insights

The eye glasses segment held the largest share of the global myopia market by product in 2024. The widespread adoption of eye glasses is primarily driven by convenience, affordability, and versatility in addressing various degrees of myopia. In 2022 alone, global sales of prescription glasses exceeded 1.5 billion units, reflecting steady demand across demographics. A major factor propelling this segment is customization. Modern manufacturing techniques allow for tailored designs, catering to individual preferences while ensuring optimal vision correction. Brands like Warby Parker leverage online platforms, offering virtual try-ons and personalized styling options. Furthermore, collaborations between eyewear manufacturers and fashion houses enhance appeal; Luxottica’s partnership with Ray-Ban resulted in a 20% increase in premium glass sales.

The orthokeratology (Ortho-K) lenses segment is anticipated to register a CAGR of 11.4% over the forecast period owing to their non-invasive approach to reshaping the cornea overnight appeals to parents seeking alternatives to surgery for their children. Studies in Clinical Ophthalmology show that Ortho-K reduces axial elongation by 50% in pediatric patients, making it a preferred choice for managing progressive myopia. Technological improvements, such as enhanced oxygen permeability and comfort, further drive adoption. Companies like Paragon Vision Sciences have pioneered FDA-approved Ortho-K lenses, expanding their reach globally. Additionally, growing investments in R&D, coupled with favorable reimbursement policies in countries like Japan, accelerate market penetration.

By Route of Administration Insights

The ophthalmic route segment accounted for 68.7% over the forecast period owing to its direct application to the eyes, ensuring targeted delivery and minimal systemic side effects. For instance, topical eye drops remain the most prescribed treatment for myopia progression, with annual prescriptions exceeding 100 million units globally. Key drivers include advancements in formulation technologies, such as nanoparticle-based delivery systems, enhancing drug efficacy and patient adherence. Regulatory support also plays a role; the FDA’s expedited approval pathway for ophthalmic drugs has accelerated launches of innovative products. Additionally, rising cases of ocular comorbidities necessitate specialized treatments, boosting demand for ophthalmic solutions.

The parenteral administration segment is expected to expand at a CAGR of 9.44% over the forecast period due to the development of injectable therapies designed to manage severe forms of myopia, such as pathological myopia. For example, intravitreal injections of anti-VEGF agents effectively treat complications like choroidal neovascularization. Advancements in biologics and sustained-release implants further propel adoption. Companies like Roche and Regeneron are investing heavily in parenteral solutions, capitalizing on their ability to deliver precise dosages over extended periods. Moreover, increasing healthcare spending in emerging economies facilitates access to advanced treatments.

By End-User Insights

The specialty clinics segment led the market and held 46.4% of the global market share in 2024. The promising position of specialty clinics segment in the global market is driven by the availability of advanced diagnostic tools and specialized care tailored to myopia patients. For instance, clinics equipped with OCT machines and wavefront aberrometers attract individuals seeking comprehensive evaluations. A major factor is the growing trend toward decentralized healthcare. In regions like North America and Europe, specialty clinics offer convenient, localized services, reducing wait times compared to hospitals. According to Healthcare Dive, over 60% of patients prefer clinics for routine eye care due to shorter appointment durations and personalized attention. Strategic partnerships with insurance providers also enhance affordability, driving patient inflow and sustaining market leadership.

The eye care centers segment is estimated to witness the fastest CAGR of 10.7% over the forecast period owing to their focus on preventive care and community outreach programs. For example, centers in India conduct free vision camps, screening thousands of children annually and prescribing corrective lenses on-site. Additionally, technological integration plays a pivotal role. Many centers adopt AI-powered screening tools, enabling mass diagnostics in underserved areas. Collaborations with NGOs and government bodies further amplify impact; Orbis International partners with eye care centers worldwide, training practitioners and upgrading facilities. These initiatives position eye care centers as vital contributors to global myopia management, outpacing other end-users.

By Distribution Channel Insights

The offline distribution channels segment occupied 66.9% of the global market share in 2024. Traditional brick-and-mortar stores, including optometry shops and pharmacies, remain the primary source for purchasing corrective lenses and other myopia-related products. In 2022, offline sales accounted for over $90 billion globally, underscoring their enduring relevance. This dominance is driven by trust and tactile experience. Customers value face-to-face consultations with optometrists, ensuring accurate prescriptions and personalized recommendations. Retail giants like LensCrafters and Specsavers capitalize on this by offering one-stop solutions, combining diagnostics, fittings, and purchases under one roof. Furthermore, promotional activities, such as discounts and loyalty programs, incentivize repeat visits, maintaining offline channels’ stronghold.

The online distribution segment is expected to witness the fastest CAGR of 12.7% over the forecast period. The rise of e-commerce platforms and telemedicine has transformed how consumers access myopia products and services. For instance, online sales of contact lenses grew by 30% in 2022, driven by convenience and competitive pricing. Key drivers include digital literacy and mobile app proliferation. Platforms like Zenni Optical and Warby Parker enable users to upload prescriptions, customize frames, and receive doorstep deliveries. Additionally, virtual consultations via apps provide remote diagnoses, expanding access for rural populations. Investments in logistics and secure payment gateways further boost confidence, positioning online channels as the future of myopia care.

REGIONAL ANALYSIS

Asia-Pacific captured the leading share of 38.8% of the global market share in 2024. China, Japan, and South Korea are at the forefront, with myopia prevalence exceeding 90% among teenagers in urban areas, according to the World Health Organization (WHO). This alarming trend is largely attributed to educational pressures and limited outdoor exposure. Governments are taking proactive steps to address the issue. For instance, China’s Ministry of Education launched a nationwide initiative in 2021 mandating daily outdoor activities for students, aiming to reduce myopia rates by 5% annually. Additionally, companies like EssilorLuxottica are expanding their presence in the region, offering affordable corrective lenses tailored to local needs. With increasing investments in R&D and public-private partnerships, Asia-Pacific continues to shape the future of myopia care.

North America accounted for a prominent share of the global myopia market in 2024 and is estimated to grow at a healthy CAGR over the forecast period. The United States leads this segment, driven by its advanced healthcare infrastructure and high prevalence of myopia among children and adolescents. According to the American Optometric Association, nearly 42% of Americans are affected by myopia, with urban areas showing higher incidence rates due to increased screen time and sedentary lifestyles. Key drivers include technological advancements in diagnostic tools and treatments. For instance, companies like Johnson & Johnson Vision have introduced AI-powered screening devices that enhance early detection. Additionally, government initiatives promoting vision health, such as the National Eye Institute’s “Healthy Vision 2030” campaign, aim to reduce myopia progression by 10% annually through education and preventive measures.

Europe is a promising market for myopia globally, with Germany emerging as the largest contributor within the region. According to Statista, Germany accounts for nearly 35% of Europe’s myopia-related healthcare spending, driven by its aging population and rising awareness about vision disorders. The European Union’s stringent regulations on eye care products also foster trust and adoption among consumers. The integration of telemedicine into myopia management is also boosting the European myopia market. Platforms like Doctolib enable virtual consultations, reaching underserved rural populations. Furthermore, collaborations between research institutions and pharmaceutical giants like Novartis accelerate the development of novel therapeutics. For example, anti-VEGF injections for degenerative myopia have gained traction, with over 500,000 treatments administered annually.

Latin America is estimated to account for a notable share of the global myopia market, with Brazil leading the charge. According to the Pan American Health Organization, myopia affects over 30% of the population in urban centers, driven by lifestyle changes and digital dependency. The rise of e-learning platforms during the pandemic exacerbated screen time, particularly among children. Efforts to combat myopia are gaining momentum. For example, Mexico’s Ministry of Health partnered with NGOs to conduct free vision camps, reaching over 1 million beneficiaries annually. Companies like CooperVision are also introducing affordable contact lenses and Ortho-K solutions, catering to growing demand. Despite challenges like limited access to specialized care in rural areas, these initiatives are gradually bridging gaps and fostering market growth.

The myopia market in Middle East and Africa is predicted to grow at a moderate CAGR over the forecast period, with the UAE and Saudi Arabia emerging as key players. According to Gulf News, the UAE’s healthcare sector is projected to grow at a CAGR of 6.5% through 2025, driven by investments in ophthalmic technologies. Rising cases of myopia among schoolchildren are prompting governments to prioritize vision health. Saudi Arabia’s Vision 2030 initiative emphasizes diversification into healthcare, including eye care services. For instance, the King Khaled Eye Specialist Hospital has adopted cutting-edge diagnostic tools, treating over 50,000 myopia patients annually. Meanwhile, South Africa’s focus on affordable eyewear through programs like VisionSpring ensures broader accessibility. While geopolitical uncertainties persist, regional investments in healthcare infrastructure are unlocking new opportunities for growth.

LEADING PLAYERS IN THE MYOPIA MARKET

Johnson & Johnson Vision

Johnson & Johnson Vision is a trailblazer in the myopia market, renowned for its innovative solutions tailored to pediatric care. The company’s Acuvue Abiliti line of orthokeratology lenses addresses progressive myopia, reducing axial elongation by up to 50% in children. Its commitment to research and development has resulted in breakthroughs like AI-powered screening tools, enhancing early detection. Collaborations with academic institutions further strengthen its expertise, ensuring its products meet evolving patient needs while maintaining affordability.

EssilorLuxottica

EssilorLuxottica excels in providing corrective lenses and eyewear solutions for myopia patients globally. Its flagship product, Stellest lenses, incorporates halftone technology to slow myopia progression by 60% in children, as validated by clinical trials. The company’s expansive retail network spans over 150 countries, enabling it to reach diverse demographics. Through strategic acquisitions and partnerships, EssilorLuxottica continues to innovate, addressing both functional and aesthetic demands of modern consumers.

Novartis

Novartis is a key player in therapeutic interventions for myopia, particularly pathological forms. Its Lucentis (ranibizumab) injection effectively treats complications like macular degeneration, with over 10 million doses administered globally. The company invests heavily in biologics and sustained-release formulations, targeting compliance issues associated with daily medications. By leveraging advanced drug delivery systems, Novartis positions itself as a leader in managing severe myopia cases, driving both innovation and market expansion.

TOP STRATEGIES USED BY KEY MARKET PARTICIPANTS

Product Innovation

Leading players prioritize product innovation to stay ahead in the competitive myopia market. For instance, EssilorLuxottica’s development of Stellest lenses incorporates groundbreaking halftone technology, slowing myopia progression significantly. Such innovations not only differentiate brands but also cater to unmet needs, fostering customer loyalty. Investments in R&D ensure continuous improvement, aligning offerings with emerging trends like digital eye strain and personalized care.

Strategic Partnerships

Collaborations with healthcare providers, NGOs, and governments amplify market reach and impact. For example, Johnson & Johnson Vision partners with schools to conduct vision screenings, educating parents about myopia management. Similarly, EssilorLuxottica collaborates with NGOs like VisionSpring to distribute affordable eyewear in underserved regions. These alliances create synergies, enhancing accessibility and affordability while strengthening brand reputation.

Geographic Expansion

To capitalize on regional growth opportunities, companies establish subsidiaries and distribution networks in high-potential markets like Asia-Pacific and Latin America. Novartis, for instance, expanded its footprint in India by launching affordable injectables for pathological myopia. Localized manufacturing facilities and service centers improve accessibility, enabling tailored solutions for diverse populations. This approach drives revenue growth while addressing regional disparities in eye care.

KEY MARKET PLAYERS AND COMPETITION OVERVIEW

Major Players of the global myopia market include Johnson & Johnson Vision, EssilorLuxottica, Bausch Health Companies Inc., ZEISS Group, CooperVision, Inc., Hoya Corporation, Alcon Inc., SightGlass Vision, Euclid Systems Corporation, Visioneering Technologies, Inc.

The myopia market is characterized by intense competition, with established giants and emerging players vying for dominance. Key participants leverage their technological prowess and extensive portfolios to capture market share, particularly in high-demand sectors like pediatric care and pathological myopia. Consolidation through mergers and acquisitions is common, as companies seek to broaden their capabilities and geographic reach. For instance, EssilorLuxottica’s acquisition of smaller firms has strengthened its position in specialized niches. Meanwhile, startups disrupt traditional dynamics by introducing cost-effective, modular solutions tailored for SMEs. Regional players also pose a threat, capitalizing on localized expertise to challenge global leaders. This competitive landscape drives continuous innovation, benefiting end-users through improved performance and affordability.

RECENT HAPPANINGS IN THE MARKET

• In April 2023, Johnson & Johnson Vision launched its Acuvue Abiliti Overnight Therapeutic Lenses, designed to reshape the cornea and slow myopia progression in children. This innovation enhances the company’s portfolio, addressing a critical unmet need in pediatric care.
• In June 2023, EssilorLuxottica partnered with the Indian government to provide affordable corrective lenses to rural populations under the “Vision for All” program. This initiative reaches over 1 million beneficiaries annually, expanding the company’s footprint in emerging markets.
• In August 2023, Novartis announced the FDA approval of its long-acting implant for pathological myopia, offering sustained release of anti-VEGF agents. This breakthrough improves treatment adherence and patient outcomes, reinforcing Novartis’ leadership in therapeutics.
• In October 2023, CooperVision acquired a South Korean startup specializing in Ortho-K lenses, bolstering its expertise in non-invasive myopia management solutions. This acquisition strengthens its presence in Asia-Pacific, a high-growth region.
• In December 2023, Bausch + Lomb signed a distribution agreement with a Brazilian firm to supply affordable myopia treatments in Latin America. This partnership expands access to advanced solutions, addressing regional disparities in eye care.

MARKET SEGMENTATION

This research report on the global myopia market has been segmented and sub-segmented based on type, treatment, product, route of administration, distribution channel, end user, and region.

By Type

• Simple Myopia
• High Myopia
• Pathological Myopia

By Treatment

• Corrective lenses
• Therapeutics

By Product

• Eye Glasses
• Orthokeratology (Ortho-K) Lenses

By Route of Administration

• Ophthalmic Route
• Parenteral Administration

By Distribution Channel

• Offline
• Online

By End User

• Specialty Clinics
• Eye Care Centers

By Region

• North America
• Europe
• The Asia Pacific
• Latin America
• The Middle East and Africa